Drug Trial Radar · NCT06525636
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Oct 9, 2024
Primary completion
Jun 14, 2030
Study completion Jun 14, 2030
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin, Inc.
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
Conditions
- X-linked Hypophosphatemia
Interventions
KK8123Drug
Subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with TEAEsTime frame: For up to 48 weeks.
- Part 1: Percentage of participants with TEAEsTime frame: For up to 48 weeks.
- Part 2: Number of participants with TEAEsTime frame: For up to 48 weeks.
- Part 2: Percentage of participants with TEAEsTime frame: For up to 48 weeks.
- Part 1: Change from baseline for haematology laboratories valuesTime frame: For up to 48 weeks.
- Part 2: Change from baseline for haematology laboratories valuesTime frame: For up to 48 weeks.
- Part 1: Change from baseline for clinical chemistry laboratories valuesTime frame: For up to 48 weeks.
- Part 2: Change from baseline for clinical chemistry laboratories valuesTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for FSHTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for FSHTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for estradiolTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for estradiolTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for temperatureTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for temperatureTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for pulse rateTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for pulse rateTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for respiratory rateTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for respiratory rateTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for systolic and diastolic blood pressureTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for systolic and diastolic blood pressureTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for QTTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for QTTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for QTcTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for QTcTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for QTCFTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for QTCFTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for QRSTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for QRSTime frame: For up to 48 weeks.
- Part 1: Change from baseline in continuous variables for heart rateTime frame: For up to 48 weeks.
- Part 2: Change from baseline in continuous variables for heart rateTime frame: For up to 48 weeks.
- Part 1: The presence or absence of abnormality on ectopic mineralization, any sign of left ventricular hypertrophy or heart failures before and after administration of KK8123 on EchocardiogramTime frame: For up to 48 weeks.
- Part 2: The presence or absence of abnormality on ectopic mineralization, any sign of left ventricular hypertrophy or heart failures before and after administration of KK8123 on EchocardiogramTime frame: For up to 48 weeks.
- Part 1: Before and after administration presented at each time point in categorical variables for renal ultrasoundTime frame: For up to 48 weeks.
- Part 2: Before and after administration presented at each time point in categorical variables for renal ultrasoundTime frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by maximum plasma concentration (Cmax)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by maximum plasma concentration (Cmax)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by maximum serum concentration (tmax)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by maximum serum concentration (tmax)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by area under the serum concentration time curve from zero to last detectable time point (AUClast)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by area under the serum concentration time curve from zero to last detectable time point (AUClast)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by the area under the serum concentration time curve from zero to infinity (AUC00-inf)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by the area under the serum concentration time curve from zero to infinity (AUC00-inf)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by apparent volume of distribution (V/F)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by apparent volume of distribution (V/F)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by terminal half-life (t1/2)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by terminal half-life (t1/2)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by apparent clearance (CL/F)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by apparent clearance (CL/F)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by maximum plasma concentration steady state (Cmax,ss)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by maximum plasma concentration steady state (Cmax,ss)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by time to maximum serum concentration steady state (tmax,ss)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by time to maximum serum concentration steady state (tmax,ss)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations over time by area under the serum concentration curve within a dosing interval at steady state (AUCtau,ss)Time frame: For up to 48 weeks.
- Part 2: KK8123 concentrations over time by area under the serum concentration curve within a dosing interval at steady state (AUCtau,ss)Time frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by time to steady stateTime frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by time to steady stateTime frame: For up to 48 weeks.
- Part 1: KK8123 concentrations by accumulation ratioTime frame: For up to 48 weeks.
- Part 2: KK8123 concentrations by accumulation ratioTime frame: For up to 48 weeks.
- Part 1: To evaluate the effect of single and multiple SC administrations of KK8123 on serum phosphorus levelsTime frame: For up to 48 weeks.
- Part 2: To evaluate the effect of multiple SC administrations of KK8123 on serum phosphorus levelsTime frame: For up to 48 weeks.
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
University of California - San Francisco
San Francisco, California · Recruiting
Yale Center for XLH/ Yale University School of Medicine
New Haven, Connecticut · Recruiting
Indiana University School of Medicine University Hospital
Indianapolis, Indiana · Recruiting
Mayo Clinic
Rochester, Minnesota · Not yet recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Bone Research and Education Center
Oakville, Ontario, Canada · Recruiting
Hoptial Bictre
Le Kremlin-Bicêtre, Paris, France · Recruiting
Institute of Osteology and Biomechanics (IOBM)
Hamburg, Germany · Recruiting
Universitaetsklinikum Wurzburg
Würzburg, Germany · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.